368 related articles for article (PubMed ID: 32246495)
1. Differential brain region-specific expression of MeCP2 and BDNF in Rett Syndrome patients: a distinct grey-white matter variation.
Pejhan S; Siu VM; Ang LC; Del Bigio MR; Rastegar M
Neuropathol Appl Neurobiol; 2020 Dec; 46(7):735-750. PubMed ID: 32246495
[TBL] [Abstract][Full Text] [Related]
2. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease.
Pejhan S; Rastegar M
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33429932
[TBL] [Abstract][Full Text] [Related]
3. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome.
Chen L; Chen K; Lavery LA; Baker SA; Shaw CA; Li W; Zoghbi HY
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5509-14. PubMed ID: 25870282
[TBL] [Abstract][Full Text] [Related]
4. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients.
Lilja T; Wallenborg K; Björkman K; Albåge M; Eriksson M; Lagercrantz H; Rohdin M; Hermanson O
Epigenetics; 2013 Mar; 8(3):246-51. PubMed ID: 23348913
[TBL] [Abstract][Full Text] [Related]
5. The ups and downs of BDNF in Rett syndrome.
Sun YE; Wu H
Neuron; 2006 Feb; 49(3):321-3. PubMed ID: 16446133
[TBL] [Abstract][Full Text] [Related]
6. Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome.
Okabe Y; Takahashi T; Mitsumasu C; Kosai K; Tanaka E; Matsuishi T
PLoS One; 2012; 7(4):e35354. PubMed ID: 22532851
[TBL] [Abstract][Full Text] [Related]
7. Impairment of adenosinergic system in Rett syndrome: Novel therapeutic target to boost BDNF signalling.
Miranda-Lourenço C; Duarte ST; Palminha C; Gaspar C; Rodrigues TM; Magalhães-Cardoso T; Rei N; Colino-Oliveira M; Gomes R; Ferreira S; Rosa J; Xapelli S; Armstrong J; García-Cazorla À; Correia-de-Sá P; Sebastião AM; Diógenes MJ
Neurobiol Dis; 2020 Nov; 145():105043. PubMed ID: 32798727
[TBL] [Abstract][Full Text] [Related]
8. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression.
Chang Q; Khare G; Dani V; Nelson S; Jaenisch R
Neuron; 2006 Feb; 49(3):341-8. PubMed ID: 16446138
[TBL] [Abstract][Full Text] [Related]
9. Metformin Induces MeCP2 in the Hippocampus of Male Mice with Sex-Specific and Brain-Region-Dependent Molecular Impact.
Arezoumand KS; Roberts CT; Rastegar M
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672521
[TBL] [Abstract][Full Text] [Related]
10. Adenosinergic System and BDNF Signaling Changes as a Cross-Sectional Feature of RTT: Characterization of
Miranda-Lourenço C; Rosa J; Rei N; Belo RF; Lopes AL; Silva D; Vieira C; Magalhães-Cardoso T; Viais R; Correia-de-Sá P; Sebastião AM; Diógenes MJ
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003438
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression and Regulation of Brain-Derived Neurotrophic Factor (BDNF) mRNA Isoforms in Brain Cells from Mecp2(308/y) Mouse Model.
Rousseaud A; Delépine C; Nectoux J; Billuart P; Bienvenu T
J Mol Neurosci; 2015 Aug; 56(4):758-767. PubMed ID: 25634725
[TBL] [Abstract][Full Text] [Related]
12. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
[TBL] [Abstract][Full Text] [Related]
13. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.
Chapleau CA; Calfa GD; Lane MC; Albertson AJ; Larimore JL; Kudo S; Armstrong DL; Percy AK; Pozzo-Miller L
Neurobiol Dis; 2009 Aug; 35(2):219-33. PubMed ID: 19442733
[TBL] [Abstract][Full Text] [Related]
14. Regulation mechanism and research progress of MeCP2 in Rett syndrome.
Yang W; Pan H
Yi Chuan; 2014 Jul; 36(7):625-30. PubMed ID: 25076025
[TBL] [Abstract][Full Text] [Related]
15. The MeCP2E1/E2-BDNF-
Pejhan S; Del Bigio MR; Rastegar M
Front Cell Dev Biol; 2020; 8():763. PubMed ID: 32974336
[TBL] [Abstract][Full Text] [Related]
16. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome.
Ogier M; Wang H; Hong E; Wang Q; Greenberg ME; Katz DM
J Neurosci; 2007 Oct; 27(40):10912-7. PubMed ID: 17913925
[TBL] [Abstract][Full Text] [Related]
17. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.
Cheung AY; Horvath LM; Grafodatskaya D; Pasceri P; Weksberg R; Hotta A; Carrel L; Ellis J
Hum Mol Genet; 2011 Jun; 20(11):2103-15. PubMed ID: 21372149
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Transcranial Focused Ultrasound for Rett Syndrome.
Tsai SJ
Med Sci Monit; 2016 Oct; 22():4026-4029. PubMed ID: 27786169
[TBL] [Abstract][Full Text] [Related]
19. Restoration of motor learning in a mouse model of Rett syndrome following long-term treatment with a novel small-molecule activator of TrkB.
Adams I; Yang T; Longo FM; Katz DM
Dis Model Mech; 2020 Nov; 13(11):. PubMed ID: 33361117
[TBL] [Abstract][Full Text] [Related]
20. Early intervention with psychostimulants or antidepressants to increase methyl-CpG-binding protein 2 (MeCP2) expressions: a potential therapy for Rett syndrome.
Pan CH; Tsai S
Med Sci Monit; 2012 Jan; 18(1):HY1-3. PubMed ID: 22207122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
